{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:05:59Z","timestamp":1789549559158,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.msard.2022.104090","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T19:23:53Z","timestamp":1659813833000},"page":"104090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Neutropenia complicating anti-CD20 treatment in patients with multiple sclerosis: A retrospective case series and a systematic review of reported cases"],"prefix":"10.1016","volume":"68","author":[{"given":"Lucrezia","family":"Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Dinoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Bratina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fulvio","family":"Pasquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Manganotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.104090_bib0001","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3899\/jrheum.130526","article-title":"Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab","volume":"41","author":"Abdulkader","year":"2014","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.msard.2022.104090_bib0002","article-title":"Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab","author":"Alba Su\u00e1rez","year":"2021","journal-title":"Neurologia"},{"key":"10.1016\/j.msard.2022.104090_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102155","article-title":"Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab","volume":"43","author":"Auer","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104090_bib0004","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1941874420936438","article-title":"Severe delayed-onset neutropenia induced by Ocrelizumab","volume":"11","author":"Baird-Gunning","year":"2021","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.msard.2022.104090_bib0005","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1212\/WNL.0000000000006924","article-title":"Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis","volume":"92","author":"Cohen","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104090_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103357","article-title":"Lymphopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: Prevalence, predicting factors and clinical outcomes","volume":"57","author":"Dinoto","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104090_bib0007","doi-asserted-by":"crossref","DOI":"10.1177\/13524585221078825","article-title":"Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II","author":"G\u00e4rtner","year":"2022","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2022.104090_bib0008","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.104090_bib0009","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/ane.13225","article-title":"Rituximab in multiple sclerosis at general hospital level","volume":"141","author":"Hellgren","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.msard.2022.104090_bib0010","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1007\/s10072-021-05379-9","article-title":"Late-onset neutropenia (LON) recur in a MS patient after the second cycle of ocrelizumab: a case report","volume":"42","author":"Maniscalco","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2022.104090_bib0011","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","article-title":"Anti-CD20 therapies for multiple sclerosis: current status and future perspectives","volume":"269","author":"Margoni","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.104090_bib0012","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1007\/s10072-021-05357-1","article-title":"Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient","volume":"42","author":"Marrodan","year":"2021","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2022.104090_bib23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"ORATORIO clinical investigators. Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.104090_bib0013","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1212\/WNL.54.11.2147","article-title":"Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor","volume":"54","author":"Openshaw","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2022.104090_bib0014","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ccr3.5299","article-title":"Severe late-onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: A case report","volume":"10","author":"Rauniyar","year":"2022","journal-title":"Clin. Case Reports"},{"key":"10.1016\/j.msard.2022.104090_bib0016","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.neurol.2021.06.007","article-title":"Late-onset neutropenia after anti-CD20 therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG antibody-associated disease: A prospective study","volume":"178","author":"Rigal","year":"2022","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.msard.2022.104090_bib0017","article-title":"Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases","author":"Rigal","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104090_bib0018","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.msard.2017.12.005","article-title":"Severe neutropenia after rituximab-treatment of multiple sclerosis","volume":"20","author":"Rissanen","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104090_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bcr-2019-233569","article-title":"Rituximab-induced late-onset neutropenia","volume":"12","author":"Sahu","year":"2019","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.msard.2022.104090_bib0020","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1002\/art.30427","article-title":"Late-onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections","volume":"63","author":"Tesfa","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.msard.2022.104090_bib0021","article-title":"Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis \u2013 A cohort study","volume":"7","author":"Torgauten","year":"2021","journal-title":"Mult. Scler. J. - Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2022.104090_bib24","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2022.104090_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2019.116603","article-title":"Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: a case report and review of the literature","volume":"409","author":"Zanetta","year":"2020","journal-title":"J. Neurol. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:04:02Z","timestamp":1761901442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822005983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":23,"alternative-id":["S2211034822005983"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104090","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutropenia complicating anti-CD20 treatment in patients with multiple sclerosis: A retrospective case series and a systematic review of reported cases","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104090"}}